This distinction is clinically relevant, as it suggests that AR antagonists may be beneficial for hyperandrogenic PCOS cases, while ER modulators could be more appropriate for non-hyperandrogenic PCOS patients. Here, ESR1 is linked to polycystic ovary syndrome.